EPI

First Wave BioPharma, Inc. Announces $9 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

Retrieved on: 
Monday, February 28, 2022
GLOBE, Niclosamide, BOCA, U.S. Securities and Exchange Commission, Ulcerative colitis, Nutrient, Security (finance), NASDAQ, SEC filing, Diarrhea, Digestion, COVID-19, Company, Clinical trial, Sale, Cystic fibrosis, LLC, Form, Acquisition, Exercise, FW, Degenerative disease, Exocrine pancreatic insufficiency, Park, Patient, EPI, Fats, Telephone, SEC, Pharmaceutical industry, Nasdaq

The closing of the offering is expected to occur on or about March 2, 2022, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about March 2, 2022, subject to the satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • The gross proceeds from the offering are expected to be approximately $9 million.
  • These forward-looking statements are subject to risks and uncertainties including, among other things, the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of proceeds from the registered direct offering.

Packers' Head Coach Matt LaFleur Named EdjSports Coach of the Year for the Second Consecutive Year

Retrieved on: 
Thursday, February 10, 2022
Green Bay Packers, Statistics, Critical, Risk, Injury, Pittsburgh Steelers, WAGR, Sport, Head coach, Entrepreneurship, Top Five, Coach of the Year, No, NOS, Epis, EPI, Week, Corporation, Capital, Football Outsiders, Giant, Lafleur, PATS, GWC, NFL, Saint, Champion, COVID-19, Probability, Vikings, Industry, Tutoring, Risk management, CCI

Louisville, Kentucky and New York, New York--(Newsfile Corp. - February 10, 2022) - Champion Gaming Group Inc. (TSXV: WAGR) (formerly, Prime City One Capital Corp.) ("Champion Gaming" or the "Company") announced today that EdjSports, Champion Gaming's premier sports intelligence firm leveraging its predictive and prescriptive analytical models and win probability applications, named Green Bay Packers' Head Coach, Matt LaFleur, as its 2021 EdjSports Coach of the Year. This marks the second consecutive year LaFluer has won this award.

Key Points: 
  • Colts' Head Coach, Frank Reich, who was in the top spot through Week 17, finished second.
  • Chargers' Head Coach, Brandon Staley, who finished first in CCI (Offensive Play Calling Ranking), came in third overall.
  • Chiefs' Head Coach, Andy Reid, and Bills' Head Coach, Sean McDermott, round out the top five in the 2021 EdjSports Coach Rankings.
  • "Matt LaFleur repeats as our Coach of the Year," said Frank Frigo, Champion Gaming's Chief Innovation Officer and Co-Founder of EdjSports.

Global Mini LED Display Market, to 2027 - by Form, Application, Panel Size and Region

Retrieved on: 
Thursday, February 10, 2022
HGC, SONY, Growth, EPI, Electronics, Mississippi ex rel. Hood v. AU Optronics Corp., Investment, AOT, Competitive landscape, AUO, Adaptation, TrafFix Devices, Inc. v. Marketing Displays, Inc., Car, R, Apple Inc., AOC, Japan Display, Research report, Mini, SWOT, LLC, InnoLux Corporation, MSI, Epistar, Smartphone, LED, Panhard AML, Analysis, COVID-19, Television set, Video game console, Retail

By region, the global mini LED display market is divided into Europe, North America, Asia Pacific, Middle East & Africa, and South America.

Key Points: 
  • By region, the global mini LED display market is divided into Europe, North America, Asia Pacific, Middle East & Africa, and South America.
  • Product Development & Innovation: The report provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
    Manufacturing Cost Analysis: Cost-share of various components in mini LED displays, cost analysis of mini LED displays, Unit Cost Analysis of mini LED displays, Component Cost Analysis - mini LED displays
    The global Mini LED display market report answers questions such as:
    What is the market size and forecast of the global mini LED display Market?
  • What is the market share of the leading players in the global mini LED display market?
  • What modes and strategic moves are considered favorable for entering the global mini LED display market?

First Wave BioPharma to Participate in the 2022 BIO CEO & Investor Conference

Retrieved on: 
Monday, February 7, 2022
Niclosamide, Nutrient, EPI, Exocrine pancreatic insufficiency, Company, Ulcerative colitis, Digestion, Patient, Fats, Cystic fibrosis, Diarrhea, FW, COVID-19, Pharmaceutical industry

First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

Key Points: 
  • First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
  • First Wave BioPharmas niclosamide portfolio is led by two clinical programs in Phase 2 clinical trials: FW-COV for COVID-19 gastrointestinal infections and FW-UP for ulcerative proctitis (UP) and ulcerative proctosigmoiditis.
  • The Company is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
  • First Wave BioPharma is headquartered in Boca Raton, Florida.

Edward Jones Selects Exit Planning Institute as Sole Provider of Exit Planning Education and Credentials

Retrieved on: 
Monday, January 31, 2022
Consulting, Professional Services, Finance, Partnership, EPI, Program, LinkedIn, CEPA, Education, Financial adviser

Edward Jones has selected Exit Planning Institute (EPI) as the sole provider of exit planning training, education and credentials for Edward Jones advisors.

Key Points: 
  • Edward Jones has selected Exit Planning Institute (EPI) as the sole provider of exit planning training, education and credentials for Edward Jones advisors.
  • EPI is a leader in the field of exit planning and offers the Certified Exit Planning Advisor (CEPA) designation for professional advisors who want to serve business owners more effectively and holistically.
  • Were delighted to partner with a firm of Edward Jones size and reach, said Scott Snider, President, EPI.
  • Exit Planning institute (EPI) was formed in 2005 to serve the educational and resource needs of professional business advisors.

BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 1, 2022 TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS

Retrieved on: 
Monday, January 17, 2022
Nature, Research, Conference, Antibody, Prostate cancer, Cytokine, Bio-Techne, NASDAQ, EPI, Intelliscore, Solution, CST, ACD, ISH, Diagnosis, FDA, Workflow, Drug discovery, ELISA, Medical imaging

The replay will be available from 11:00 a.m. CST on Tuesday, February 1, 2022, until 11:00 p.m. CST on Tuesday, March 1, 2022.

Key Points: 
  • The replay will be available from 11:00 a.m. CST on Tuesday, February 1, 2022, until 11:00 p.m. CST on Tuesday, March 1, 2022.
  • Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow.
  • These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment.
  • With thousands of products in its portfolio, Bio-Techne generated approximately $931 million in net sales in fiscal 2021 and has approximately 2,700 employees worldwide.

First Wave BioPharma Provides Update on Adrulipase (FW-EPI) Clinical Program

Retrieved on: 
Thursday, January 13, 2022
PERT, Nature, Patient, International, Stomach, Niclosamide, Clinical trial, Fats, Weight loss, BOCA, Diarrhea, Nutrient, Malabsorption, NASDAQ, EPI, CEO, Absorption, Cystic Fibrosis Foundation, GLOBE, Standard of care, Cystic fibrosis, Ulcerative colitis, U.S. Securities and Exchange Commission, Acquisition, USPTO, Program, Patent, Company, Method, Digestion, Food, Yarrowia, INN, Steatorrhea, First wave, Lipase, Security (finance), Abdominal pain, Exocrine pancreatic insufficiency, International nonproprietary name, FW, Medical imaging, Pharmaceutical industry

BOCA RATON, Fla., Jan. 13, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases, today provided an update on its adrulipase (FW-EPI) clinical program and advances involving adrulipase.

Key Points: 
  • BOCA RATON, Fla., Jan. 13, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases, today provided an update on its adrulipase (FW-EPI) clinical program and advances involving adrulipase.
  • First Wave BioPharma has filed two new provisional patent applications pertaining to adrulipase with the U.S. Patent and Trademark Office (USPTO).
  • This is an important step in our efforts to strengthen and expand our adrulipase intellectual property portfolio as we advance the FW-EPI clinical development program, said James Sapirstein, President and CEO of First Wave BioPharma.
  • First Wave BioPharma is pursuing parallel monotherapy and combination therapy clinical pathways with adrulipase.

First Wave BioPharma Announces Further Adjournment of Annual Meeting

Retrieved on: 
Friday, January 7, 2022
Time, FW, Nutrient, Company, Patient, Exocrine pancreatic insufficiency, Diarrhea, Board of directors, Ulcerative colitis, Proposal 2, EST, Annual Meetings of the International Monetary Fund and the World Bank Group, NASDAQ, EPI, BOCA, Cystic fibrosis, Board, Fats, GLOBE, Niclosamide, Digestion, First wave, Director, Annual general meeting, Holding company, Pharmaceutical industry, Shareholder

The adjourned meeting will be held at 9:00 a.m. EST on January 14, 2022 at the following url: www.virtualshareholdermeeting.com/FWBI2021 .

Key Points: 
  • The adjourned meeting will be held at 9:00 a.m. EST on January 14, 2022 at the following url: www.virtualshareholdermeeting.com/FWBI2021 .
  • Annual Meeting of Stockholders of First Wave BioPharma, Inc.
  • First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
  • First Wave BioPharma is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.

First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

Retrieved on: 
Thursday, January 6, 2022
Clinical trial, Vomiting, Safety, Severe acute respiratory syndrome coronavirus 2, FW, COVID-19, Food, Viral load, Acquisition, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nutrient, Emergency Use Authorization, Company, Patient, Exocrine pancreatic insufficiency, Diarrhea, Ulcerative colitis, Gastrointestinal disease, COVID, U.S. Securities and Exchange Commission, Biopharma LLC, Security (finance), CEO, NASDAQ, Șaeș, EPI, Infection, FDA, GI, Cystic fibrosis, Participation, Fats, World, Institut Pasteur Korea, GLOBE, WHO, EUA, Abdominal pain, Digestion, Part, First wave, World Health Organization, SARS2, Pharmaceutical industry, Niclosamide, Omicron, Delta

BOCA RATON, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has completed enrollment for Part 2 of the RESERVOIR Phase 2 trial evaluating FW-COV as an outpatient treatment for COVID-19-related gastrointestinal (GI) infections. FW-COV is a proprietary, oral, tablet formulation of micronized niclosamide being developed to remove SARS-CoV-2 (SARS2), the virus that causes COVID-19, from the GI tract.

Key Points: 
  • No FW-COV drug-related serious adverse events (SAEs) have been reported from the trial participants.
  • First Wave BioPharma expects to report top-line data in the first half of 2022.
  • We are very pleased to complete enrollment of the second part of the RESERVOIR trial and look forward to reporting top-line data in the coming months, stated James Sapirstein, President and CEO of First Wave BioPharma.
  • This is an important milestone for First Wave and the development of FW-COV.

Lyell Immunopharma to Participate in 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 4, 2022
COVID-19, CGMP, Food, TIL, Investor, Company, Forward-looking statement, Patient, Webcast, Goal, TCR, Conference, Private Securities Litigation Reform Act, Toxic shock syndrome, NASDAQ, SEC, Neoplasm, Compliance, Lyfe, SAN, GLOBE, CAR, EPI, Lyell, Vaccine, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (NASDAQ: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that members of its senior management team will participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 3:00 PM ET.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (NASDAQ: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that members of its senior management team will participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 3:00 PM ET.
  • Lyell expects to begin screening patients for its Phase 1 clinical trial of LYL797 by the end of the first quarter, with initial data presentation expected in 2023.
  • Novel platform technologies Gen-R and Epi-R designed to enable T cells to resist exhaustion, self-renew and proliferate to outlast and eradicate solid tumors.
  • Lyell is a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors.